S In October 2003, to reflect the gravity of the HIV AIDS crisis in sub-Saharan Africa, we extended the voluntary licence granted to Aspen Pharmacare, sub-Saharan Africa's largest generics company, for the manufacture and sale of Combivir, Epivir and Retrovir. The licence, which was originally granted in October 2001, previously was limited to only the public sector in South Africa and Zimbabwe. We have now extended the licence to cover both the public and private sectors across all of sub-Saharan Africa. In December, we reached a settlement with the South African Competition Commission to provide up to a further three licences on substantially similar terms to those granted to Aspen. s In October 2003, GSK also signed a technology transfer, supply and licence agreement with the Brazilian Government's Fundao Oswaldo Cruz Fiocruz ; for the production of a Mumps, Measles and Rubella MMR ; vaccine. It is anticipated that more than 100 million doses of the vaccine will be distributed by Fiocruz to vaccinate children in Brazil over the next five years. Puko Buss, President of Fiocruz said, "We are delighted that this technical and scientific collaboration with GSK will allow us to accelerate the development of future vaccines for commercialization by Fiocruz. Product Key Germany Product Name 1 Genotropin 36 IE, 5 TRS 2 Novorapid Penfill 100 E ml, 10x3 ml ILO 3 Prograf 1 mg, 100 KAP 4 Insulin Actrapid HM, 10x3 ml ZAM 5 Twinrix Erw. Impfdosis, 1x1 ml FER 6 Combivir, 60 FTA 7 Sandimmun Neoral 100 mg, 100 KAP 8 Casodex, 90 FTA 9 Clexane 40 0, 4 ml, 10 FER 10 Zyprexa 5 mg, 28 FTA 11 Neupogen 30 Mio E. FS Konz., 5 FER 12 Pantozol 20 mg, 30 TAB 13 Salofalk 500, 300 TMR 14 Comtess, 100 FTA 15 Sandimmun Neoral 50 mg, 100 KAP 16 Lamictal 100, 200 TAB 17 Lamisil, 28 TAB 18 Zyprexa 10 mg, 28 FTA 19 Lamictal 200, TAB 20 Saizen 8 mg Click Easy, 5 TRS 21 Neupogen 48 Mio E. FS, 5 FER 22 Lamisil, 42 TAB 23 Parkotil 1, 0, 100 TAB 24 Tambocor 100 mg, 100 TAB 25 Trusopt, 3x5 ml ATR 26 NovoNorm 2, 0 mg, 120 TAB 27 Cipramil 20 mg, 100 FTA 28 Havrix 1440 Impfdosis, 1 FER 29 Zoladex, 3 FER 30 Clexane 60 mg 0, 6 ml, 10 FER 31 Alphagan, 3x5 ml ATR 32 Pulmicort Turbohaler 200 MCG, 1 DOS 33 Lamictal 100, TAB 34 Tiapridal Tiapridex ; , 100 TAB 35 Risperdal 3 mg, 100 FTA 36 NovoNorm 1, 0 mg, 120 TAB 37 Glucobay 100 mg, 120 TAB 38 Neorecormon 10.000 IE, 6 FER 39 Depo Clinovir, 1x1ml SPA 40 Zofran 8 mg, 10 FTA 41 Prograf 5 mg, 50 KAP 42 Glucobay 50, 120 TAB 43 Litalir, 100 KAP 44 Microgynon, 3x21 DRA 45 Requip 2 mg, 84 FTA 46 Risperdal 1 mg ml, 100ml LOE 47 Zyprexa Velotab 10 mg, 28 SMT 48 Epivir 300 mg, 30 FTA 49 Risperdal 3 mg, 50 FTA 50 Prograf 1 mg, 50 KAP and tranexamic and combivir. HJ. Williams should we from do more?`? Drugs Aging 1996; 9: 307-310. Gurwitz JH, Col N, Avom J. Exclusion clinical trials in acute myocardial infarction. Accolate Accupril Accuretic Accutane * Accuzyme * acebutolol * Aceon acetazolamide * acetic acid-aluminum acetate * acetic acid ear drops * acetohexamide * acetylcysteine * Actifed-C * Actigall * Actinex Actiq PA ; Actos PA ; acyclovir * not ointment ; Adalat CC * Adderall * XR non-preferred ; Adrenalin Advair Advicor Agenerase Aggrenox Agrylin albuterol * albuterol ipratropium Aldactazide * Aldactone * Aldomet * Aldoril * Alesse * Alkeran Allegra, D allopurinol * Alocril Alomide Alphagan * alprazolam * Altoprev lowest copay ; aluminum chloride * Alupent * amantadine * Amaryl Amicar * amiloride * amiloride HCTZ * aminocaproic acid * amiodarone * amitriptyline * amoxapine * amoxicillin * amoxicillin-pot clavulanate * Amoxil * amphetamine * ampicillin * amylase-lipase-protease * Anafranil * Anakit Analpram HC Anaprox, DS * Anaspaz * Android * Ansaid * Antabuse * Anturane * Anusol-HC * Apresazide * Apresoline * Aralen * Arava Aricept Arimidex Aromasin Artane * Asacol Asendin * aspirin butalbital caffeine * aspirin caff butalbital codeine * Astelin Atarax * atenolol * atenolol chlorthalidone * Ativan * atropine * Atrovent soln. & inhaler * A T S * Augmentin * Augmentin ES Augmentin XR Auralgan * Avandamet PA ; Avandia PA ; Avelox Aventyl * Aygestin * Azathioprine * Azelex Azmacort Azopt Azulfidine * Betoptic * Betoptic S Biaxin, XL Bicitra * Biltricide bisoprolol HCTZ * Bleph-10 * Blephamide Blocadren * Brethine * Bromfed, PD, TD, DM * bromocriptine * bumetanide * Bumex * buproprion * Buspar * chlorthalidone * choline & magnesium salicylates * cholestyramine * Ciloxan cimetidine * Cin-Quin * Cipro * Ciprodex Claritin * See Generic: Loratadine ; Claritin-D 24 Hour * See loratadine D 24 Hour ; Claritin Syrup * See loratadine syrup ; Claritin Reditab Not Covered ; Claritin-D 12 Hour Not Covered ; Cleocin, Vag, T * clemastine 2.68mg * clidinium chlordiazepoxide * Climara * clindamycin * Clinoril * clobetasol ointment * clomipramine * clonazepam * clonidine * clorazepate * SD non-preferred ; clozapine * Clozaril * codeine * Cogentin * colchicine * Colestid Colyte * Combivent Combivir Compazine * Comtan Concerta Condylox Gel, Soln * Cordarone * Coreg Corgard * Cortef * Cortenema * Cortifoam Cortisporin * Cotazym Cotazym-S Coumadin * Cozaar Creon * Crixivan Crolom * cromolyn sodium * ophth ; Cuprimine cyclobenzaprine * Cyclogyl * cyclopentolate * cyclophosphamide * cyclosporine * Cycrin * Cylert * cyproheptadine * Cystospaz * Cytadren Cytomel * Cytotec * Cytovene Cytoxan and cymbalta.
In the 1980s, new metal hydride alloys were developed that were stable enough for use in a cell.
Jects genotyped as CYP2C9 * 2 * 3 were detected in Indians. We also found one CYP2C9 * 3 homozygote subject in both the Malay and Indian ethnic groups respectively. The CYP2C9 allele frequencies of Malays, Chinese and Indians for both the patient and control groups are summarized in Table 3. CYP2C9 * 1 wild type allele ; was the predominant allele and occurred in high frequencies in the Malays 0.9407 ; , Chinese 0.9764 ; and Indians 0.875 ; . CYP2C9 * 2 was not detected in the Malays and Chinese but was found among the Indians with a frequency of 0.0435. CYP2C9 * 3 occurred at a very low frequency compared to CYP2C9 * 1 in all the three ethnic groups in our study. The frequency of CYP2C9 * 3 allelic variant appeared to be lower in Chinese 0.0236 ; compared to Malays 0.0593 ; and Indians 0.0815 ; . The genotyping results of CYP2C9 in both the patient and control groups were consistent. Leung and co-workers 2001 ; reported that both CYP2C9 * 2 and CYP2C9 * 3 allelic variants were extremely uncommon in Chinese. CYP2C9 * 1 was reported as the predominant allele in Han Chinese. The frequency of CYP2C9 * 3 was 0.017, and CYP2C9 * 2 was not detected in the Chinese population Wang et al., 1995 ; . Our CYP2C9 * 1 results of the Chinese are consistent with these previous findings. The frequency of CYP2C9 * 3 in our Chinese was 0.0236, which was slightly higher compared to the Han Chinese population. The CYP2C9 * 3 frequency of Taiwanese population was 0.026 Sullivan-Klose et al., 1996 ; . The results of these studies indicate that the CYP2C9 * 3 frequencies of Chinese from different geographical locations within Asia were very low compared to Caucasians 6-10% ; Takahashi and Echizen, 2001 ; . There are substantial differences in the frequencies of.
This aerial view of Brookhaven National Laboratory in Upton, NY, displays the vastly powerful physics research machinery that allows for the production, in a parasitic mode, of radionuclides for medicine. The long narrow structure at the center is the Linear Accelerator's LINAC ; transfer tunnel that accelerates protons to 200 MeV for injection into the Alternating Gradient Synchrotron ACS ; , a 0.5-milecircumference ring. The small dark building at the end of the transfer tunnel houses the Brookhaven LINAC Isotope Producer BLIP ; , which harnesses the energy from a deflected portion of the beam to create labels for radiopharmaceuticals.
We rate Shire Market Perform based on two key concerns 1 ; threats to key drivers and 2 ; valuation. Shire's 13.8x `04 P E compares very favorably to the peer group average of 27.4x, but an '04 PEG of over 5x fairly represents the uncertainty and risk to Shire's sales and earnings in `05 and beyond - something that investors will increasingly focus on in `04. Shire should trade close to this valuation for the foreseeable future until major risk factors are addressed. The key franchises and possible risks include 1 ; Adderall XR generic competition as early as 1H05 when Hatch-Waxman exclusivity with pediatric extension ; ends in April 2005, and ANDA filings that will at the very least will create a continued, significant overhang; 2 ; flattening of HIV HBV franchise Zeffix Epivir Combivir Trizivir ; , thanks to competition from newer, more effective and convenient antivirals; 3 ; generic risk to Agrylin, Pentasa, and ProAmatine whose combined `03 sales of $280m will drop to $170m in `07; and 4 ; Fosrenol approval and marketing risks because of lanthanum heavy metal ; toxicity concerns despite analyst expectations now coming in line at around $100m in peak sales. These forces collectively threaten to hold the earnings growth in low to mid single digits unless the new management gets lucky with its non-stimulant ADHD product, guanfacine SPD-503 ; , its ADHD patch MethyPatch, or is able to license in or buy attractive new drug opportunities. The new management's efforts to revive investor confidence and create value are actively underway. Initial results are likely to focus on divesting non-core units, such as the Shire Biologics vaccine business ; . Elimination of its annual burn of about $30m can positively impact `04 operating expenses by about $0.13. News flow over the coming year could include new drug launch and clinical data such as Fosrenol launch in 1H04 and guanfacine PhIII ADHD trial data by year-end '03 - perhaps the only key upside near term. In out-licensing M&A activities are important, as Shire divests its non-core development programs and investors focus on in-licensing M&A as the key for any unexpected near term share price move. As every company needs new drugs, and strategic buyers are willing to pay up for even early stage products, investors will remain concerned Shire management may overpay. Of course, the seasoned team aims to surprise investors with upside from an attractive deal that can overcome the generic Adderall XR overhang. I'm very enthusiastic about this technology, " said David B. Vasily, M.D., a dermatologist in private practice in Bethlehem, Penn. "This is basically a new way of thinking about light and biology. You're able to rejuvenate skin without having to create an injury that requires wound repair to achieve results." Several scientific papers on photomodulation were presented last April at the annual meeting of the American Society of Laser Medicine and Surgery ASLMS ; . "These presentations were very believable. The whole biology of photomodulation made sense to me, " Dr. Vasily said. The low intensity light therapy regulates biologic activity in living cells. David B. Vasily, M.D. "You use less light energy than is emitted from a 25 watt household lightbulb, " Dr. Vasily noted. "However, there are very specific sequences of light pulses that activate certain subcellular systems and lamivudine.